Haleos Labs (NSE:HALEOSLABS) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:HALEOSLABS Haleos Labs Ltd NSE:HALEOSLABS
70 GF Score
Price ₹1,484.40
GF Value ₹1,126.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Haleos Labs Cyclically Adjusted Revenue per Share?

Haleos Labs NSE:HALEOSLABS +0.64% 70 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 70/100 and a GF Value™ of ₹1,126.27 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Haleos Labs's adjusted revenue per share for the three months ended in Jun. 2026 was ₹241.132. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-15), Haleos Labs's current stock price is ₹1484.40. Haleos Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Haleos Labs's Cyclically Adjusted PS Ratio of today is .

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Haleos Labs was 1.42. The lowest was 1.04. And the median was 1.13.


Haleos Labs  (NSE:HALEOSLABS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Haleos Labs was 1.42. The lowest was 1.04. And the median was 1.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Haleos Labs Cyclically Adjusted Revenue per Share Related Terms


Haleos Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Haleos Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleos Labs Cyclically Adjusted Revenue per Share Chart

Haleos Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1,197.26

Haleos Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1,246.74 1,197.26 0.00

NSE:HALEOSLABS vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Haleos Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haleos Labs Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haleos Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Haleos Labs's Cyclically Adjusted PS Ratio falls into.


NSE:HALEOSLABS
70GF Score
Haleos Labs Ltd NSE:HALEOSLABS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleos Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Haleos Labs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=241.132/166.1454*166.1454
=241.132

Current CPI (Jun. 2026) = 166.1454.

Haleos Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 162.215 105.961 254.351
201612 202.100 105.196 319.195
201703 185.256 105.196 292.591
201706 136.741 107.109 212.111
201709 168.795 109.021 257.239
201712 219.905 109.404 333.957
201803 178.997 109.786 270.885
201806 198.077 111.317 295.640
201809 295.079 115.142 425.788
201812 340.959 115.142 491.991
201903 339.367 118.202 477.016
201906 303.808 120.880 417.574
201909 252.703 123.175 340.860
201912 153.822 126.235 202.454
202003 138.328 124.705 184.295
202006 181.048 127.000 236.852
202009 204.165 130.118 260.695
202012 220.281 130.889 279.616
202103 245.884 131.771 310.028
202106 252.299 134.084 312.627
202109 286.971 135.847 350.975
202112 301.022 138.161 361.995
202203 308.375 138.822 369.071
202206 272.076 142.347 317.562
202209 268.716 144.661 308.624
202212 292.071 145.763 332.912
202303 200.791 146.865 227.151
202306 247.027 150.280 273.106
202309 228.660 151.492 250.778
202312 238.429 152.924 259.042
202403 276.251 153.035 299.918
202406 306.147 155.789 326.499
202409 259.636 157.882 273.225
202412 279.858 158.323 293.685
202503 294.684 157.552 310.758
202506 272.923 159.755 283.840
202509 269.162 162.289 275.558
202512 313.540 163.281 319.041
202603 248.312 164.272 251.143
202606 241.132 166.145 241.132

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Haleos Labs (NSE:HALEOSLABS) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Haleos Labs and its competitors.
Is Haleos Labs' Cyclically Adjusted Revenue per Share too high?
Haleos Labs' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Haleos Labs has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Haleos Labs' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Haleos Labs and its competitors. Haleos Labs's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,126.27, compared to a current price of ₹1,484.40 — trading 31.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Haleos Labs' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?

Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued. The current stock price of ₹1,484.40 is trading 31.8% above its estimated GF Value™ of ₹1,126.27. GuruFocus considers Haleos Labs to be Significantly Overvalued.

Key valuation signals for NSE:HALEOSLABS:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹1,126.27 vs. price of ₹1,484.40 (31.8% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haleos Labs Business Description

Other Exchanges 540679:India
Address Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
70GF Score

Get the complete analysis for NSE:HALEOSLABS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,484.40
Price
₹1,126.27
GF Value